Current radiotracers to image neurodegenerative diseases

Abstract The term of neurodegenerative diseases covers a heterogeneous group of disorders that are distinguished by progressive degeneration of the structure and function of the nervous system such as dementias, movement disorders, motor neuron disorders, as well as some prion disorders. In recent y...

Full description

Saved in:
Bibliographic Details
Main Authors: Solveig Tiepolt (Author), Marianne Patt (Author), Gayane Aghakhanyan (Author), Philipp M. Meyer (Author), Swen Hesse (Author), Henryk Barthel (Author), Osama Sabri (Author)
Format: Book
Published: SpringerOpen, 2019-07-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_8ae2f6274a3a43bca7aac68d33f291a6
042 |a dc 
100 1 0 |a Solveig Tiepolt  |e author 
700 1 0 |a Marianne Patt  |e author 
700 1 0 |a Gayane Aghakhanyan  |e author 
700 1 0 |a Philipp M. Meyer  |e author 
700 1 0 |a Swen Hesse  |e author 
700 1 0 |a Henryk Barthel  |e author 
700 1 0 |a Osama Sabri  |e author 
245 0 0 |a Current radiotracers to image neurodegenerative diseases 
260 |b SpringerOpen,   |c 2019-07-01T00:00:00Z. 
500 |a 10.1186/s41181-019-0070-7 
500 |a 2365-421X 
520 |a Abstract The term of neurodegenerative diseases covers a heterogeneous group of disorders that are distinguished by progressive degeneration of the structure and function of the nervous system such as dementias, movement disorders, motor neuron disorders, as well as some prion disorders. In recent years, a paradigm shift started for the diagnosis of neurodegenerative diseases, for which successively clinical testing is supplemented by biomarker information. In research scenarios, it was even proposed recently to substitute the current syndromic by a biological definition of Alzheimer's diseases. PET examinations with various radiotracers play an important role in providing non-invasive biomarkers and co-morbidity information in neurodegeneration. Information on co-morbidity, e.g. Aβ plaques and Lewy-bodies or Aβ plaques in patients with aphasia or the absence of Aβ plaques in clinical AD patients are of interest to expand our knowledge about the pathogenesis of different phenotypically defined neurodegenerative diseases. Moreover, this information is also important in therapeutic trials targeting histopathological abnormalities. The aim of this review is to present an overview of the currently available radiotracers for imaging neurodegenerative diseases in research and in routine clinical settings. In this context, we also provide a short summary of the most frequent neurodegenerative diseases from a nuclear medicine point of view, their clinical and pathophysiological as well as nuclear imaging characteristics, and the resulting need for new radiotracers. 
546 |a EN 
690 |a Alzheimer's disease 
690 |a Parkinsonian syndromes 
690 |a Primary progressive aphasia 
690 |a Frontotemporal dementia 
690 |a PET 
690 |a SPECT 
690 |a Medical physics. Medical radiology. Nuclear medicine 
690 |a R895-920 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n EJNMMI Radiopharmacy and Chemistry, Vol 4, Iss 1, Pp 1-23 (2019) 
787 0 |n http://link.springer.com/article/10.1186/s41181-019-0070-7 
787 0 |n https://doaj.org/toc/2365-421X 
856 4 1 |u https://doaj.org/article/8ae2f6274a3a43bca7aac68d33f291a6  |z Connect to this object online.